(919) 237-4897 info@t3dtherapeutics.com

T3D Therapeutics announced the addition of three new members to its Advisory Board complementing Alzheimer’s disease and CNS expertise with pharmaceutical licensing, clinical development and business acumen; Jason Kralic Ph.D., Stuart Hobbs, Pharm.D., and Wesley Protheroe. MBA.

Mr. Protheroe is an accomplished CEO with extensive experience serving on both for-profit and non-profit Boards of Directors. He was President & CEO of Gerber Life Insurance from 2002-2013, and had previously held key management positions at Procter & Gamble, PepsiCo, and Sara Lee Corporation. He served on the Board of Gerber Life and the Gerber Baby Food companies for over a decade, and was a member of the Novartis U.S. Corporation Board from 2002-2007. He also has served on the Boards of several non-profits, including the Direct Marketing Association, the Direct Marketing Education Foundation, and the Atlanta Humane Society. Mr. Protheroe holds an MBA from Columbia University.

Dr. Hobbs has greater than 30 years of experience in pharmaceutical drug development across Regulatory, Clinical and Preclinical drug development strategy. He is presently Senior Director in Global Regulatory Labeling at GSK and is leading Labeling Teams in the development of Prescribing Information within the Respiratory Therapeutic Area. He has more than 10 years of Regulatory Labeling Strategy experience including: Respiratory, CNS, Antiviral, Urology, Androgens, Estrogens, and Musculoskeletal therapeutic areas. Prior to that, Stuart held leadership positions in the Musculoskeletal CEDD and Clinical Research groups at GSK and GSK heritage companies, leading clinical and matrix teams in clinical development across cardiovascular, CNS, dermatology, metabolic, and urology therapeutic areas.

Dr. Kralic is a neuroscience-trained business development executive who served as Head of Business Development for the Neurosciences Therapy Area Unit at GlaxoSmithKline. His responsibilities included leading the development and implementation of the BD strategy for Neurosciences R&D, coordination and prioritization of licensing/M&A opportunities, including leading technical and commercial due diligence and valuation activities, and facilitating relationships with alliance partners. He most recently led divestment of a Phase 3-ready Alzheimer’s disease program from GSK to Roivant Biosciences in December 2014. Jason joined GSK in 2009 as Director, Scientific Licensing in Worldwide Business Development covering late stage development and was promoted in 2011 to manage all Neurosciences R&D BD. Prior to GSK, Jason served in scientific licensing roles at UCB Pharma and Schwarz Biosciences. Jason holds a Ph.D. in pharmacology from the University of North Carolina at Chapel Hill School of Medicine and completed post-doctoral training at the University of Zurich.